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inpatient care and drug costs represented about 50% and 27% respectively of over-
all expenses. The increase by 24.4% polytherapy patients mean costs as compared
to monotherapy raised to 72% [IC 95: 44-106%] after adjustment on age, gender and
presence of severe comorbidity. CONCLUSIONS: Polytherapy in epilepsy is associ-
ated with substantial higher direct costs.
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OBJECTIVES: To develop a tool to estimate the first-year per member and total
health plan costs associated with monitoring of MS therapies in the United States.
METHODS: Data were incorporated into an interactive tool designed to allow a
health plan to estimate their costs for monitoring. MS prevalence was based on the
literature. The default value for the proportion of MS patients treated with immu-
nomodulators was assumed at 95% and adjusted IMS data were used for default
market share inputs. Current Procedural Terminology (CPT) codes corresponding
to the monitoring and administration procedures recommended by each product’s
prescribing information (PI) were identified. Charges associated with each CPT
code were assigned using physician fee schedule software based on Medicare
charges with default values set at 150%. PI recommendations were used for the
proportion being monitored and the frequency of monitoring. In cases where a PI
recommended only individuals with specific characteristics undergo monitoring, a
database analysis identifying all individuals with a diagnosis of MS in the i3 InVi-
sion Data Mart (Ingenix, Eden Prairie, MN) was used to estimate the proportion of
patients who may require that specific monitoring. RESULTS: The tool yielded
average per patient and health plan costs expected with MS therapy monitoring.
The tool conservatively estimates that the average per member first-year monitor-
ing and administration costs ranged from $0 for glatiramer acetate to $3279 for
natalizumab. Based on default values, the estimated annual costs of monitoring for
all MS therapies for a million member health plan is $519,451. CONCLUSIONS:
Estimating the economic impact of FDA-recommended MS therapy monitoring
allows health plans to more closely assess the total cost of MS. This tool allows
health plans to individualize inputs to estimate the plan-specific economic impact
of MS therapy monitoring.
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OBJECTIVES: Botulinum toxin A (BTA) injections are indicated for the management
of neurological movement disorders, including arm spasticity (AS) and cervical
dystonia (CD). This study calculated the cost per care episode for two BTA: Botox®
and Dysport®. The analysis was completed for 20 countries around the world.
METHODS: Doses of BTA are expressed in non-interchangeable units: Botox® is
available in “Allergan units” whereas Dysport® is provided in 500 “Speywood
units”. Recommended dosages were derived from country SmPCs/PIs. Cost analy-
sis was based on official list prices and expressed in 2011 euros, using exchange
rates as of end of May 2011. The cost per care episode was calculated using avail-
able recommended dosages for each product (country’s own or average of other
countries) combined with price per vial in each country. RESULTS: For AS, recom-
mended total injection dosage per patient for Dysport is 1000 units in all countries
where indicated in SmPCs; for Botox®, it is 300U per patient based on recom-
mended dosages in the USA and France. For CD, dosages for Dysport® are 500U per
patient; whereas 200U of Botox® is recommended per patient. Considered with the
respective prices per vial in each country, Dysport® cost per patient per care epi-
sode for AS was less than Botox® in 17 (89%) of the 19 countries (average 15% less
across countries). The difference was 20% or higher in nearly half (47%) of coun-
tries. In CD, these differences were even greater with Dysport® cost per patient was
40% or less versus Botox in 45% of countries (average 36% less across countries).
CONCLUSIONS: Considering cost per patient per care episode based on recom-
mended dosages in SmPCs/PIs, Dysport® remains cheaper versus Botox in most
countries. When extrapolated to a national level, substantial savings could be re-
alized by using Dysport® in the treatment of AS and CD.
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OBJECTIVES: The aim of this study was to calculate the incremental cost-effective-
ness ratio of the different Disease Modifying Drugs (DMD) used as first-line treat-
ments (interferons IM IFN-1a, SC IFN-1a, SC IFN-1b and glatiramer acetate, GA)
in Remitting-Relapsing Multiple Sclerosis (RRMS) in Spain. METHODS: A Markov
model was developed to simulate the progression of a cohort of patients with
RRMS, during a period of 10 years. Seven health states, defined by the EDSS, were
considered in the model. Patients with an EDSS score of less than 6.0 were assumed
to be treated with one of DMD. In addition, all patients were assumed to receive
symptomatic treatment. The monthly transition probabilities of the model were
obtained from the literature. The analysis was performed from the societal per-
spective, in which both direct and indirect (losses in productivity) healthcare costs
(€, 2010) were included. A discount rate of 3% was applied to both costs and results.
RESULTS: GA was the less costly strategy (€322,510), followed by IM IFN-1a (€
329.595), SC IFN-1b (€ 333.925) and SC IFN-1a (€ 348.208). IM IFN-1a has
shown the best efficacy results with 4,176 quality-adjusted life year (QALY),
followed by SC IFN-1a (4,158 QALY), SC IFN-1b (4,157 QALY) and GA (4,117
QALY). Incremental costs per QALY gained with IM IFN-1a were €-1,005,194/
QALY, €-223,397/QALY, and €117,914/QALY in comparison to SC IFN-1a, SC
IFN-1b and GA, respectively. CONCLUSIONS: First-line treatment with GA is the
less costly strategy for the treatment of patients with RRMS. Treatment with IM
IFN-1a is a dominant strategy (lower cost and higher QALY) compared with SC
IFN-1a and SC IFN-1b. However, IM IFN-1a is not a cost-effective strategy versus
GA, because incremental cost per QALY gained with IM IFN-1a exceeds the €30,000
per QALY threshold, commonly used in Spain.
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OBJECTIVES: Multiple sclerosis (MS) is the neurologic disability that can dramati-
cally affect the quality of life (QoL) of patients and their families. Family life, eco-
nomic status, and social interaction may be affected by somatic symptoms of the
disease. Approximately 70,000 people in the Islamic Republic of Iran are affected by
MS. Under budgetary constraints,Cost-effectiveness and cost-utility analyses
(CEA/CUAs) are useful tools to assess the tradeoff between the added costs and
potential benefits (e.g., improved patient outcomes) of new therapies. METHODS:
The primary objective of this analysis was to evaluate the cost-effectiveness of
Avonex compared with Betaferon from the Iranian Ministry of Health(MoH) over a
2-year time horizon. The relative risk reduction (RRR) method was used to compare
reduction in relapse rates and disease progression data from pivotal randomized
double-blind placebo-controlled clinical trials of the DMDs. The evaluation was
conducted from the perspective of a Iranian health care sector (direct medical costs
and indirect cost considered). The primary economic endpoint was cost per relapse
avoided . Costs and outcomes occurring in the second year were discounted 3% to
bring to 2010 present values. One way sensitivity analyses were conducted on key
input variables to assess their impact on cost per relapse avoided. RESULTS: The
2-year reductions in clinical relapses for treatment with Avonex,Betaferon were
0.69 and 0.60 relatively. In the base case analysis, Avonex had the most favorable
costs per relapse avoided (2652778 Rials) rather than Betaferon. Sensitivity analy-
ses showed that these results were robust to changes in key input parameters, such
as the number of relapses and disease progression steps in untreated patients, the
progression rates, the average cost of relapse. CONCLUSIONS: This evaluation sug-
gests that IFN -1a SC injection(Avonex) represent the most cost-effective DMDs
for the treatment of RRMS, where cost-effectiveness is defined as cost per relapse
avoided,rather than Bataferon.
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OBJECTIVES: Early intervention in the course of acute migraine attacks has been
recently advocated as a way to further reduce the economic burden and suffering
of patients due to this condition. The aim of this study was to investigate the
cost-effectiveness of such a strategy using almotriptan in the Spanish setting.
METHODS: An economic evaluation was conducted from the Spanish societal and
public health system perspective based on patient-level data collected in the “Act
when Mild” study. Incremental cost-effectiveness ratios (ICER) were determined in
terms of attack duration, loss of productive time and quality-adjusted life days
(QALDs). Monte Carlo simulation was used to derive cost-effectiveness acceptabil-
ity curves. RESULTS: Early treatment led on average to shorter attack duration, less
productive time lost, better quality of life, and was overall cost-saving from a
societal point of view with a probability of 97%. In terms of publicly reimbursed
drug costs only, though, non-early treatment was always slightly less expensive.
From the public health system perspective the (bootstrap) mean ICER of early treat-
ment amounted to €0.12 per migraine hour avoided, €0.42 per hour of productive
time lost avoided, and €6.62 per QALD gained. Considering willingness to pay val-
ues of €1 to reduce attack duration by one hour, €5 to avoid the loss of one produc-
tive hour, or €55 to gain one QALD (equivalent to €20,000 per QALY), the probability
that early treatment was cost-effective from the public health system perspective
was, respectively, 96%, 96%, and 98%. These results remained robust in sensitivity
analyses that accounted for the uncertainty surrounding the major elements of the
economic evaluation. CONCLUSIONS: Compared to non-early treatment, early
treatment of acute migraine attacks with almotriptan when pain is still mild is with
high probability cost-saving from the Spanish societal perspective and cost-effec-
tive from the public health system point of view.
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